{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:06:05Z","timestamp":1777712765902,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12325-022-02156-8","type":"journal-article","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T11:07:01Z","timestamp":1652353621000},"page":"3180-3198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials"],"prefix":"10.1007","volume":"39","author":[{"given":"Josep","family":"Franch-Nadal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1306-7784","authenticated-orcid":false,"given":"Samuel J. P.","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barnaby","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Gallego Est\u00e9banez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2156_CR1","unstructured":"International Diabetes Federation (IDF). Diabetes Atlas\u201410th Edition. 2021. Available at: https:\/\/diabetesatlas.org\/data\/en\/country\/209\/gb.html [Last accessed December 10, 2021]."},{"key":"2156_CR2","doi-asserted-by":"crossref","unstructured":"Soriguer F, Goday A, Bosch-Comas A, Bordi\u00fa E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55(1):88\u201393","DOI":"10.1007\/s00125-011-2336-9"},{"key":"2156_CR3","doi-asserted-by":"crossref","unstructured":"Rojo-Mart\u00ednez G, Vald\u00e9s S, Soriguer F, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study. Sci Rep. 2020;10:2765.","DOI":"10.1038\/s41598-020-59643-7"},{"key":"2156_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-8603-9-17","volume":"9","author":"J Lopez-Bastida","year":"2013","unstructured":"Lopez-Bastida J, Boronat M, Moreno JO, et al. Costs, outcomes and challenges for diabetes care in Spain. Global Health. 2013;9:17.","journal-title":"Global Health"},{"key":"2156_CR5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"2156_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ahj.2005.09.015","volume":"152","author":"C Stettler","year":"2006","unstructured":"Stettler C, Allemann S, J\u00fcni P, Cull CA, Holman RR, Egger M, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. Am Heart J. 2006;152:27\u201338.","journal-title":"Am Heart J"},{"key":"2156_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419\u201330.","journal-title":"Lancet"},{"key":"2156_CR8","doi-asserted-by":"crossref","unstructured":"ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"issue":"4","key":"2156_CR9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2337\/dc19-0573","volume":"43","author":"M Mata-Cases","year":"2020","unstructured":"Mata-Cases M, Rodr\u00edguez-S\u00e1nchez B, Mauricio D, et al. The association between poor glycemic control and health care costs in people with diabetes: a population-based study. Diabetes Care. 2020;43(4):751\u20138.","journal-title":"Diabetes Care"},{"key":"2156_CR10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1186\/s12913-020-05360-w","volume":"20","author":"M Mata-Cases","year":"2020","unstructured":"Mata-Cases M, Mahon J, Mauricio D, et al. Improving management of glycaemic control in people with T2DM in primary care: estimation of the impact on the clinical complications and associated costs. BMC Health Serv Res. 2020;20:803.","journal-title":"BMC Health Serv Res"},{"key":"2156_CR11","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u201391.","journal-title":"N Engl J Med"},{"key":"2156_CR12","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117\u201325.","DOI":"10.1016\/S0140-6736(08)60104-X"},{"key":"2156_CR13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"2156_CR14","doi-asserted-by":"crossref","unstructured":"Gomez-Peralta F, Escalada San Mart\u00edn FJ, Men\u00e9ndez Torre E, et al. Recomendaciones de la Sociedad Espa\u00f1ola de Diabetes (SED) para el tratamiento farmacol\u00f3gico de la hiperglucemia en la diabetes tipo 2: Actualizaci\u00f3n 2018. Endocrinol Diabetes Nutr. 2018;65:611\u201324.","DOI":"10.1016\/j.endinu.2018.08.004"},{"key":"2156_CR15","unstructured":"European Medicines Agency (EMA). Human Medicines Highlights 2020. 2020. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/report\/human-medicines-highlights-2020_en.pdf [Last accessed December 15, 2021]."},{"key":"2156_CR16","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg S\u00d8, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42:2272\u201381.","journal-title":"Diabetes Care"},{"key":"2156_CR17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321:1466\u201380.","journal-title":"JAMA"},{"key":"2156_CR18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394:39\u201350.","journal-title":"Lancet"},{"issue":"1","key":"2156_CR19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-019-00736-6","volume":"11","author":"SC Bain","year":"2020","unstructured":"Bain SC, Hansen BB, Malkin SJP, Nuhoho S, Valentine WJ, Chubb B, Hunt B, Capehorn M. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: long-term cost-effectiveness analyses based on the pioneer clinical trial programme. Diabetes Ther. 2020;11(1):259\u201377.","journal-title":"Diabetes Ther"},{"key":"2156_CR20","doi-asserted-by":"crossref","unstructured":"Malkin SJP, Hunt B, Huisman EL, Grand TS, Chubb B. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. Diabetes Res Clin Pract. 2021;175:108759.","DOI":"10.1016\/j.diabres.2021.108759"},{"key":"2156_CR21","unstructured":"European Medicines Agency. Press release: First oral GLP-1 treatment for type 2 diabetes. 2020. Available at: https:\/\/www.ema.europa.eu\/en\/news\/first-oral-glp-1-treatment-type-2-diabetes [Last accessed November 5, 2021]."},{"key":"2156_CR22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.2337\/diacare.27.9.2262","volume":"27","author":"American Diabetes Association Consensus Panel","year":"2004","unstructured":"American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27:2262\u20135.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"2156_CR23","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(Suppl 1):S5-26.","journal-title":"Curr Med Res Opin"},{"key":"2156_CR24","doi-asserted-by":"crossref","unstructured":"Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, Let al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1):S27\u201340.","DOI":"10.1185\/030079904X1980"},{"key":"2156_CR25","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","volume":"17","author":"P McEwan","year":"2014","unstructured":"McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17:714\u201324.","journal-title":"Value Health"},{"issue":"2","key":"2156_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.gaceta.2009.07.011","volume":"24","author":"J Lopez Bastida","year":"2010","unstructured":"Lopez Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J. A proposed guideline for economic evaluation of health technologies. Gac Sanit. 2010;24(2):154\u201370.","journal-title":"Gac Sanit"},{"key":"2156_CR27","unstructured":"World Health Organisation. Global Health Observatory data repository: Life tables by country (Spain). 2020. Available at: https:\/\/apps.who.int\/gho\/data\/view.main.LT62210?lang=en [Last accessed November 5, 2021]."},{"key":"2156_CR28","doi-asserted-by":"crossref","unstructured":"Briggs AH, Weinstein MC, Fenwick EA Karnon J, Sculpher MJ, Paltiel AD, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health 2012;15:835\u201342.","DOI":"10.1016\/j.jval.2012.04.014"},{"key":"2156_CR29","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1111\/dom.13804","volume":"21","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Saugstrup T, Buse JB, Donsmark M, Zacho J, Davies MJ. Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: the PIONEER 1 randomized clinical trial as an example. Diabetes Obes Metab. 2019;21:2203\u201310.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2156_CR30","first-page":"443","volume":"66","author":"R Reyes-Garc\u00eda","year":"2019","unstructured":"Reyes-Garc\u00eda R, Moreno-P\u00e9rez \u00d3, Tejera-P\u00e9rez C, et al. Document on a comprehensive approach to type 2 diabetes mellitus. Endocrinol Diabetes Nutr (Engl Ed). 2019;66(7):443\u201358.","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"2156_CR31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jval.2016.10.004","volume":"20","author":"M Willis","year":"2017","unstructured":"Willis M, Asseburg C, Nilsson A, Johnsson K, Kartman B. Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: Informing economic modeling. Value Health. 2017;20:357\u201371.","journal-title":"Value Health"},{"issue":"6","key":"2156_CR32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1463-1326.2006.00686.x","volume":"9","author":"D Russell-Jones","year":"2007","unstructured":"Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes\u2013causes, effects and coping strategies. Diabetes Obes Metab. 2007;9(6):799\u2013812.","journal-title":"Diabetes Obes Metab"},{"key":"2156_CR33","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","volume":"50","author":"UK Hypoglycaemia Study Group","year":"2007","unstructured":"UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140\u20137.","journal-title":"Diabetologia"},{"issue":"2","key":"2156_CR34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13696998.2019.1681436","volume":"23","author":"JJ Gorgojo-Mart\u00ednez","year":"2020","unstructured":"Gorgojo-Mart\u00ednez JJ, Malkin SJP, Mart\u00edn V, Hall\u00e9n N, Hunt B. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: once-weekly semaglutide versus empagliflozin. J Med Econ. 2020;23(2):193\u2013202.","journal-title":"J Med Econ"},{"issue":"10","key":"2156_CR35","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s12325-020-01464-1","volume":"37","author":"V Mart\u00edn","year":"2020","unstructured":"Mart\u00edn V, Vidal J, Malkin SJP, Hall\u00e9n N, Hunt B. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide and sitagliptin in the spanish setting. Adv Ther. 2020;37(10):4427\u201345.","journal-title":"Adv Ther"},{"key":"2156_CR36","unstructured":"Instituto Nacional de Estad\u00edstica [National Institute of Statistics]. \u00cdndices nacionales: general y de grupos ECOICOP [National indices: general and ECOICOP groups]. 2021. Available at: https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=22344#!tabs-tabla [Last accessed November 1, 2021]."},{"issue":"4","key":"2156_CR37","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","volume":"17","author":"A Beaudet","year":"2014","unstructured":"Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462\u201370.","journal-title":"Value Health"},{"issue":"1","key":"2156_CR38","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1477-7525-11-90","volume":"11","author":"M Evans","year":"2013","unstructured":"Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, Harris S. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90.","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"2156_CR39","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1464-5491.2005.01657.x","volume":"22","author":"AJ Lee","year":"2005","unstructured":"Lee AJ, Morgan CL, Morrissey M, Wittrup-Jensen KU, Kennedy-Martin T, Currie CJ. Evaluation of the association between the EQ-5D (health-related utility) and body mass index (obesity) in hospital-treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetes. Diabet Med. 2005;22(11):1482\u20136.","journal-title":"Diabet Med"},{"issue":"9","key":"2156_CR40","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1007\/s11136-014-0712-x","volume":"23","author":"JT Lauridsen","year":"2014","unstructured":"Lauridsen JT, L\u00f8nborg J, Gundgaard J, Jensen HH. Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries. Qual Life Res. 2014;23(9):2645\u201350.","journal-title":"Qual Life Res"},{"issue":"8","key":"2156_CR41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1185\/030079906X115757","volume":"22","author":"CJ Currie","year":"2006","unstructured":"Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523\u201334.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2156_CR42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0213-9111(02)71933-X","volume":"16","author":"JA Sacrist\u00e1n","year":"2002","unstructured":"Sacrist\u00e1n JA, Oliva J, Del Llano J, Prieto L, Pinto JL. Qu\u00e9 es una tecnolog\u00eda sanitaria eficiente en Espa\u00f1a? [What is an efficient health technology in Spain?]. Gac Sanit. 2002;16(4):334\u201343.","journal-title":"Gac Sanit"},{"key":"2156_CR43","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","volume":"36","author":"K Khunti","year":"2013","unstructured":"Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411\u20137.","journal-title":"Diabetes Care"},{"key":"2156_CR44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","volume":"22","author":"M Husain","year":"2020","unstructured":"Husain M, Bain SC, Jeppesen OK, Lingvay I, S\u00f8rrig R, Treppendahl MB, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22:442\u201351.","journal-title":"Diabetes Obes Metab"},{"key":"2156_CR45","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. (EMPA-REG OUTCOME Investigators). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117\u201328.","DOI":"10.1056\/NEJMoa1504720"},{"key":"2156_CR46","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA et al. (LEADER Trial Investigators). Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311\u201322.","DOI":"10.1056\/NEJMoa1603827"},{"issue":"3","key":"2156_CR47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"key":"2156_CR48","doi-asserted-by":"crossref","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2019; dci190066.","DOI":"10.2337\/dci19-0066"},{"issue":"9","key":"2156_CR49","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jval.2020.04.1832","volume":"23","author":"L Si","year":"2020","unstructured":"Si L, Willis MS, Asseburg C, et al. Evaluating the ability of economic models of diabetes to simulate new cardiovascular outcomes trials: a report on the ninth mount hood diabetes challenge. Value Health. 2020;23(9):1163\u201370.","journal-title":"Value Health"},{"key":"2156_CR50","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s13300-019-00681-4","volume":"10","author":"M Willis","year":"2019","unstructured":"Willis M, Asseburg C, Nilsson A, Neslusan C. Challenges and opportunities associated with incorporating new evidence of drug-mediated cardioprotection in the economic modeling of type 2 diabetes: a literature review. Diabetes Ther. 2019;10:1753\u201369.","journal-title":"Diabetes Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-022-02156-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-022-02156-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:03:20Z","timestamp":1656443000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-022-02156-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["2156"],"URL":"https:\/\/doi.org\/10.1007\/s12325-022-02156-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,12]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}